Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children’s Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Future Horizons | Analyst targets range from $75 to $215, reflecting diverse views on Sarepta's potential for expansion into new indications and geographic markets |
Market Dominance | Delve into Sarepta's leadership in the DMD market, leveraging extensive experience and relationships to maintain a competitive edge |
Financial Prowess | Explore Sarepta's impressive financial performance, with Q3 revenues of $430 million and projections of up to $4.1 billion by 2026 |
Elevidys Triumph | Sarepta's gene therapy for DMD exceeds revenue expectations, driving substantial growth despite recent safety concerns and fierce market competition |
Metrics to compare | SRPT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSRPTPeersSector | |
---|---|---|---|---|
P/E Ratio | 25.5x | −2.5x | −0.5x | |
PEG Ratio | 0.18 | −0.09 | 0.00 | |
Price / Book | 3.9x | 1.5x | 2.6x | |
Price / LTM Sales | 3.2x | 13.0x | 2.9x | |
Upside (Analyst Target) | 161.3% | 134.6% | 57.2% | |
Fair Value Upside | Unlock | 4.9% | 8.9% | Unlock |